About Senores Pharmaceuticals
Senores Pharmaceuticals is a company based in Buford (United States) founded in 2017 by Anar Swapnil Shah, Swapnil Jatinbhai Shah, and Pinkyben Jatinbhai Shah. Senores Pharmaceuticals has raised $3.66 million across 3 funding rounds from investors including Prakash Sanghvi, Jayanti Sanghvi and Jigar Sanghvi. The company has 194 employees as of March 31, 2024. Senores Pharmaceuticals offers products and services including Complex Generics and API and Intermediates.
- Headquarter Buford, United States
- Employees 194 as on 31 Mar, 2024
- Founders Anar Swapnil Shah, Swapnil Jatinbhai Shah, Pinkyben Jatinbhai Shah
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Senores Pharmaceuticals Ltd.
-
Annual Revenue
$46.47 M (USD)85.67as on Mar 31, 2025
-
Net Profit
$6.85 M (USD)86.14as on Mar 31, 2025
-
EBITDA
$10.4 M (USD)116.26as on Mar 31, 2025
-
Total Equity Funding
$3.66 M (USD)
in 3 rounds
-
Latest Funding Round
$2.67 M (USD), Angel Round
Oct 29, 2021
-
Investors
& 13 more
-
Employee Count
194
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Senores Pharmaceuticals
Senores Pharmaceuticals is a publicly listed company on the NSE with ticker symbol SENORES in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Senores Pharmaceuticals
Senores Pharmaceuticals offers a comprehensive portfolio of products and services, including Complex Generics and API and Intermediates.
Complex generics are manufactured to fulfill a variety of medical needs, with affordability and high quality being ensured through global certifications
API and intermediates are produced for pharmaceutical applications, supporting the creation of cost-effective generics across markets
People of Senores Pharmaceuticals
Unlock access to complete
Funding Insights of Senores Pharmaceuticals
Senores Pharmaceuticals has successfully raised a total of $3.66M across 3 strategic funding rounds. The most recent funding activity was a Angel Round of $2.67 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Senores Pharmaceuticals
Senores Pharmaceuticals has secured backing from 14 investors, including angel investors. Prominent investors backing the company include Prakash Sanghvi, Jayanti Sanghvi and Jigar Sanghvi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PS
Prakash Sanghvi |
-
|
Locked | Locked | Locked |
|
JS
Jayanti Sanghvi |
-
|
Locked | Locked | Locked |
|
JS
Jigar Sanghvi |
-
|
Locked | Locked | Locked |
Investor details for Senores Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Senores Pharmaceuticals
Investment portfolio details for Senores Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Senores Pharmaceuticals
Detailed financials for Senores Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Senores Pharmaceuticals Comparisons
Peer comparison for Senores Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Senores Pharmaceuticals
Detailed competitors of Senores Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Senores Pharmaceuticals
Complete news archive for Senores Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Senores Pharmaceuticals
Senores Pharmaceuticals was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Senores Pharmaceuticals is headquartered in Buford, United States. It is registered at Buford, Georgia, United States.
Senores Pharmaceuticals is a funded company, having raised a total of $3.66M across 3 funding rounds to date.
As of Mar 31, 2024, the latest employee count at Senores Pharmaceuticals is 194.
Annual revenue of Senores Pharmaceuticals is $46.47M as on Mar 31, 2025.
Senores Pharmaceuticals was established in 2017 and is based in Buford, United States. Operations are centered on the manufacturing of pharmaceutical drugs within the healthcare sector. The company is led by co-founders Anar Swapnil Shah, Swapnil Jatinbhai Shah as managing director, and Pinkyben Jatinbhai Shah. Drug production activities are conducted to support pharmaceutical needs, with a focus on standard industry practices in the region.
Senores Pharmaceuticals offers Complex Generics and API and Intermediates.
Yes, Senores Pharmaceuticals is publicly traded on NSE under the ticker symbol SENORES.
Senores Pharmaceuticals has 14 investors. Key investors include Prakash Sanghvi, Jayanti Sanghvi, Jigar Sanghvi, Manoj Sanghvi, and Shantilal Sanghvi.
The ticker symbol of Senores Pharmaceuticals is SENORES on NSE.
The valuation of Senores Pharmaceuticals is $5.71M as of Oct 2021.